| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f6be7b5f316f050e9151b3afd8936f7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2005-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70fa68151a98f0605cc4c338fffc048b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_195e517d8593ea1f321e7dfde8d9b1ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_833f34f162f10c53d6f18fa8c82a725c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0719ffc5179e94a30be8ecab3f5067a9 |
| publicationDate |
2011-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2005315534-B2 |
| titleOfInvention |
Cytotoxic antibody directed against type B lymphoid hematopoietic proliferations |
| abstract |
The invention concerns a monoclonal antibody directed against the CD20 antigen, whereof the variable region of each of the light chains is encoded by a sequence having at least 70 % identity with the murine nucleic acid sequence SEQ ID NO: 5, the variable region of each of the heavy chains is encoded by a sequence having at least 70 % identity with the murine nucleic acid sequence SEQ ID NO: 7 and the constant regions of light chains and of heavy chains are constant regions derived from a non-murine species. The invention also concerns the use of said antibody to activate FcγRIII receptors of immune effector cells, and for making a drug, in particular for treating leukemia or a lymphoma. |
| priorityDate |
2004-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |